In NSCLC, blocking the Hh signaling pathway using the SMO antagonist (SANT-1) restores the expression of E-cadherin; meanwhile, it decreases the expression of Snail and ABCG2 in EGFR-TKIs resistant NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.